Our top pick for
Apria Inc is a medical instruments & supplies business based in the US. Apria shares (APR) are listed on the NASDAQ and all prices are listed in US Dollars. Apria employs 6,080 staff and has a trailing 12-month revenue of around $1.1 billion.
|Latest market close||$37.50|
|52-week range||$27.89 - $38.15|
|50-day moving average||$37.37|
|200-day moving average||$34.13|
|Wall St. target price||$38.33|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$1.66|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2022-09-18)||N/A|
|1 month (2022-08-25)||N/A|
|3 months (2022-06-25)||N/A|
|6 months (2022-03-28)||37.5|
|1 year (2021-09-29)||4.46%|
|2 years (2020-09-25)||N/A|
|3 years (2019-09-25)||N/A|
|5 years (2017-09-25)||N/A|
Valuing Apria stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Apria's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Apria's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 23x. In other words, Apria shares trade at around 23x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
However, Apria's P/E ratio is best considered in relation to those of others within the medical instruments & supplies industry or those of similar companies.
Apria's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $218 million.
The EBITDA is a measure of a Apria's overall financial performance and is widely used to measure a its profitability.
To put Apria's EBITDA into context you can compare it against that of similar companies.
|Revenue TTM||$1.1 billion|
|Operating margin TTM||9.4%|
|Gross profit TTM||$905 million|
|Return on assets TTM||9.09%|
|Return on equity TTM||96.92%|
|Market capitalisation||$1.3 billion|
TTM: trailing 12 months
We're not expecting Apria to pay a dividend over the next 12 months.
You may also wish to consider:
Apria, Inc. provides integrated home healthcare equipment and related services in the United States. The company offers home respiratory therapies, including the supply of stationary and portable home oxygen equipment, and non-invasive ventilators; obstructive sleep apnea therapy devices comprising continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services; and negative pressure wound therapy products. It also provides a range of home medical equipment and other products, and services for patients with home care needs; and clinical and administrative support services, and related products and supplies to patients. Apria, Inc. was incorporated in 2018 and is headquartered in Indianapolis, Indiana. As of March 29, 2022, Apria, Inc.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.